Recipient:

Recipient Name

Adnan Dahdul, MD

Adnan M. Dahdul, M.D.

95 Frank B Murray Street
Springfield, MA 01103
United States

[email protected] Issuing Office: Office of Compliance and Biologics Quality

United States

Secondary Issuing Offices

Dear Dr. Dahdul:

The Food and Drug Administration (FDA) has completed an evaluation of your corrective actions in response to our Warning Letter CBER-26-719607 dated March 11, 2026. Based on our evaluation, it appears that you have addressed the violations contained in this Warning Letter. Future FDA inspections and regulatory activities will further assess the adequacy and sustainability of these corrections.

This letter does not relieve you from your responsibility to take all necessary steps to ensure sustained compliance with the Federal Food, Drug, and Cosmetic Act and its implementing regulations. The Agency expects you to continuously comply with the law and will monitor your state of compliance.

Sincerely,
/S/
Carrie M. Mampilly, MPH
Director, Division of Inspections and Surveillance
Office of Compliance and Biologics Quality
Center for Biologics Evaluation and Research

CC:
Mishelle Harriger, SCSO, OII, OBMI Division 1
[email protected]